Skip to main content

Table 3 Incidence of cardiovascular events and stroke in clinical trials of erythropoiesis-stimulating agents

From: 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

 

Cardiovascular events

Stroke

(/1000 patients year)

(/1000 patients year)

CHOIR

51.7

5.4

CREATE

58

7.2

TREAT

76.4

9.5

A21

15.6

2.1

Gonryo (G3–5)

21.8

8.6

  1. The events defined as cardiovascular events in each study were as follows: the events specified as primary endpoints in the CHOIR, CREATE, and TREAT studies; myocardial infarction, cerebral infarction, cerebellar infarction, lung congestion, and heart failure, which were specified as adverse events, in the A21 study; angina, myocardial infarction, heart failure, and stroke in stage G3–5 patients in the Gonryo study
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us